mitoxantrone has been researched along with Acute Lymphoid Leukemia in 104 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " CT-guided lung biopsy confirmed the diagnosis of pulmonary mucormycosis and liposomal amphotericin B therapy was started." | 7.73 | Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia. ( Salonen, JH, 2006) |
| "The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)." | 7.69 | Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994) |
| "In a phase I study, 68 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and accelerated- and blastic-phase CML received induction therapy consisting of cytarabine 3 g/m2 by infusion over 3 hours daily for 5 days, with escalating doses of mitoxantrone 40 to 80 mg/m2 over 1 to 2 days by intravenous infusion over 15 minutes." | 5.07 | Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. ( Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993) |
| " CT-guided lung biopsy confirmed the diagnosis of pulmonary mucormycosis and liposomal amphotericin B therapy was started." | 3.73 | Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia. ( Salonen, JH, 2006) |
| "From December 1995 to April 2003, 14 lymphoma and 29 acute leukemia patients were treated with high-dose cytarabine (2 g/m2 every 12 h, days 1 and 2) and mitoxantrone (10 mg/m2, days 2 and 3), followed by 300 microgram recombinant human granulocyte colony-stimulating factor per day (rhG-CSF 300 microg/d) i." | 3.72 | [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies]. ( Chang, WR; Fu, ZZ; Jin, ZM; Miao, M; Qiu, HY; Shen, YM; Sun, AN; Tang, XW; Wu, DP, 2004) |
| "The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)." | 3.69 | Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994) |
| "Clofarabine MTD was 32 mg/m(2)/d in this combination which appeared feasible and effective in this population." | 2.82 | A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). ( Baruchel, A; Bertrand, Y; Brethon, B; Cave, H; Galambrun, C; Gandemer, V; Leverger, G; Nelken, B; Plat, G; Rohrlich, P; Schmitt, C; Thomas, C; Vérité, C, 2016) |
| "Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while no patient with acute myeloid leukemia (AML) had an objective response." | 2.75 | Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. ( Arceci, RJ; Bernstein, M; Buck, S; Chang, MN; Dahl, GV; Kshirsagar, S; Lacayo, NJ; Lum, BL; O'Brien, MM; Ravindranath, Y; Sikic, BI; Weinstein, H, 2010) |
| " During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL)." | 2.73 | Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. ( Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F, 2007) |
| "Outcome of adults with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) or who relapse soon after initial response is poor." | 2.72 | Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). ( Adamczyk-Cioch, M; Dmoszynska, A; Giebel, S; Holowiecki, J; Jakubas, B; Krawczyk-Kulis, M; Lewandowski, K; Nowak, K; Palynyczko, G; Skotnicki, A, 2006) |
| "Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucemies Aigues Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course." | 2.71 | Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. ( Asnafi, V; Boiron, JM; Buzyn, A; Cayuela, JM; Dombret, H; Fiere, D; Huguet, F; Lheritier, V; Macintyre, E; Reman, O; Thomas, X; Vernant, JP; Vey, N, 2005) |
| "Idarubicin-based induction programs in acute lymphoblastic leukemia (ALL) account for 75?-?85% of complete remission rate." | 2.71 | Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients. ( Barbui, T; Bassan, R; D'Emilio, A; Di Bona, E; Lerede, T; Pogliani, E; Rodeghiero, F; Rossi, G; Vespignani, M, 2005) |
| "Overall response rate was 31% in 26 acute myelogenous leukemia and 12." | 2.71 | Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ( Bauer, KS; Bible, K; Briel, J; Colevas, AD; Garimella, TS; Gojo, I; Gore, SD; Greer, J; Karp, JE; Kaufmann, S; Passaniti, A; Ross, DD; Smith, BD; Tidwell, ML; Wright, JJ, 2005) |
| "Mitoxantrone is an active agent in the treatment of acute leukemia and demonstrates incomplete cross resistance with duanorubicin." | 2.67 | Mitoxantrone for refractory and relapsed acute leukemia. ( Bernasconi, C; Bezwoda, WR; de Bock, R; Hutchinson, RM; Mandelli, F; Winfield, DA, 1990) |
| "Thirty children with refractory acute lymphocytic leukemia (ALL) were treated with mitoxantrone, 8 mg/m2/day, for 5 days." | 2.67 | Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study. ( Estrada, J; Graham, ML; Ragab, AH; Rosen, D; Starling, KA; Wilkenson, RW; Wilkerson, RW, 1991) |
| "Mitoxantrone is a new anthracenodione derivative with a high antineoplastic activity in proliferative diseases of the haemopoietic system." | 2.67 | [Preliminary results of the treatment of acute leukemia with mitoxantrone]. ( Apel, D; Hołowiecki, J; Konecki, R; Lawniczek, T; Maj, S; Mariańska, B; Mazur, J; Pałynyczko, G; Rozmysłowicz, T; Rudzka, E, 1991) |
| "Objective response rates were 21% in breast cancer, 36% in non-Hodgkin's lymphoma, 56% in acute lymphocytic leukemia, 14% in acute nonlymphocytic leukemia, 31% in gastric cancer and 5% in primary hepatic cancer." | 2.66 | [Phase II clinical trial on mitoxantrone]. ( Gao, HR, 1989) |
| "Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL." | 2.42 | Recent advances in pediatric acute lymphoblastic and myeloid leukemia. ( Ravindranath, Y, 2003) |
| "acute lymphoblastic leukemia-type chemotherapy that incorporated high-dose cytarabine was effective in achieving an minimal residual disease-negativity rate of 69% in evaluated patients, which was also predictive of better outcome." | 1.56 | Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India. ( Banavali, S; Gujral, S; Myint, HH; Narula, G; Patkar, N; Prasad, M; Subramanian, P; Tandon, S; Tembhare, P, 2020) |
| "The treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children is challenging and new treatment options are needed." | 1.56 | Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. ( August, KJ; Gamis, AS; Guest, EM; Hays, JA; Lewing, K, 2020) |
| "Histopathological subtypes consist of Burkitt's lymphoma (BL) in 32 (43." | 1.48 | Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan. ( Anwar, S; Faizan, M; Khan, S, 2018) |
| "Children with relapsed acute lymphoblastic leukemia (ALL) typically receive vincristine-prednisone-L-asparaginase-doxorubicin reinduction chemotherapy similar to contemporary induction regimens." | 1.43 | Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. ( Fu, CH; Gaynon, PS; Sun, W; Wayne, AS; Yeo, KK, 2016) |
| " However, an effective combination with other drugs and a feasible dosage has not been identified." | 1.42 | Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party. ( Ahn, JS; Chung, JS; Jo, DY; Joo, YD; Jung, SH; Kim, DY; Kim, I; Lee, JJ; Lee, KH; Moon, JH; Park, S; Shin, HJ; Sohn, SK; Song, IC; Yang, DH, 2015) |
| "Remission induction regimens for acute lymphoblastic leukemia (ALL) in adults induce complete remission (CR) in 60-90% and cure in 20-40%." | 1.42 | Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience. ( Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Herrera-Garza, JL; Jaime-Perez, JC; Pinzón-Uresti, MA, 2015) |
| "Mitoxantrone is a reasonable replacement for daunorubicin in times of drug shortage." | 1.40 | Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. ( Bergsagel, J; Cooper, T; Daves, M; Keller, F; Lew, G; Nickel, RS; Sabnis, H, 2014) |
| "It has been shown that the human acute lymphoblastic leukemia (ALL) T cell line (RPMI 8402) selected with irinotecan (CPT-11) is transformed to a multidrug resistant (MDR) phenotype (CPT-K5) with cross-resistance to mitoxantrone (MX)." | 1.33 | Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. ( Lee, SH; Sinko, PJ; Su, Y, 2006) |
| "Superior sagittal sinus thrombosis (SSST) has been reported to be caused by coagulopathy following oral contraceptive therapy, DIC, infection around the sinus, compression from a tumor, infiltration of tumor, and an inherited deficiency of proteins C and S, but SSST associated with hematological malignancies and L-asparaginase (L-Asp) therapy is rare." | 1.33 | [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]. ( Iijima, K; Iki, S; Kida, M; Nakasone, H; Taoka, K; Urabe, A; Usuki, K; Yoshimi, A, 2006) |
| "After each course, minimal residual disease was tested by specific reverse transcriptase-polymerase chain reaction (RT-PCR) (median sensitivity, 10(-5))." | 1.31 | Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. ( Bilhou-Nabera, C; Blaise, D; Boiron, JM; Boucheix, C; Bourhis, JH; Buzyn, A; Cayuela, JM; Charrin, C; Delannoy, A; Dombret, H; Espérou, H; Fegueux, N; Fenaux, P; Fière, D; Gabert, J; Lhéritier, V; MacIntyre, E; Rigal-Huguet, F; Thomas, X; Vernant, JP, 2002) |
| "The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL." | 1.31 | Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002) |
| "We report a 20-month-old boy with acute lymphoblastic leukemia with the 11q23 translocation whose blasts markedly increased in peripheral blood after intravenous granulocyte colony-stimulating factor (G-CSF) administration, but disappeared after stopping G-CSF." | 1.30 | Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. ( Goi, K; Iijima, K; Inukai, T; Kagami, K; Kinoshita, A; Kojika, S; Mori, T; Nakazawa, S; O-Koyama, T; Sugita, K; Suzuki, T; Tezuka, T, 1998) |
| "The other patient was diagnosed with acute monoblastic leukemia (M5a) and received two autologous peripheral blood stem-cell transplantations." | 1.29 | 11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone. ( Chubachi, A; Hashimoto, K; Hayashi, Y; Miura, AB; Miura, I; Nimura, T; Ohshima, A; Seto, M; Takahashi, N; Ueda, R; Utsumi, S, 1996) |
| "Daunorubicin (DNR) is a major front-line drug in the treatment of childhood acute lymphoblastic leukaemia (ALL)." | 1.29 | In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. ( den Boer, ML; Huismans, DR; Klumper, E; Loonen, AH; Pieters, R; Veerman, AJ, 1995) |
| "The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy." | 1.29 | Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. ( Welborn, JL, 1994) |
| "Among 15 patients with acute lymphoblastic leukemia (ALL), complete remission was obtained in 5 patients (33." | 1.29 | Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. ( Atamer, MA; Büyükkeçeci, F; Keskin, A; Tombuloğlu, M, 1994) |
| "Mitoxantrone (MIT) has not been studied as a single agent in children with untreated leukemia." | 1.29 | In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. ( de Waal, FC; Hählen, K; Kaspers, GL; Klumper, E; Pieters, R; van Wering, ER; van Zantwijk, I; Veerman, AJ, 1994) |
| "Mucormycosis is a rare fungal infection that has been described mainly in oncologic and diabetic patients." | 1.29 | [Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases]. ( Cancelas, JA; Cerveró, C; García-Laraña, J; López, J; Navarro, JL; Odriozola, J; Pérez-Oteyza, J; Sánchez-Sousa, A; Sastre, JL, 1994) |
| "A 45-year-old woman with acute lymphoblastic leukemia (ALL) who failed to achieve complete remission (CR) after one course of induction chemotherapy with vincristine, daunorubicin, prednisolone and l-asparaginase was successfully treated with a high dose of cytosine arabinoside (Ara-C) and mitoxantrone." | 1.29 | CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: a case report. ( Ikeda, Y; Ishida, A; Kawai, Y; Kizaki, M; Nakajima, H; Tokuhira, M; Watanabe, K, 1996) |
| "Thirty-four adults with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside (ara-C) 3 g/m2 intravenously over 2 hours every 12 hours for six doses, followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) 125 microgram/m2 intravenously over 4 hours daily until recovery of granulocytes above 2." | 1.28 | Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. ( Anaissie, E; Beran, M; Estey, EH; Gutterman, J; Kantarjian, HM; Keating, MJ; O'Brien, S; Rios, MB, 1992) |
| " As mitoxantrone exhibits a steep dose-response curve against ovarian cancer cells and acute myeloid leukemia cells in vitro, we evaluated the safety and efficacy of high dose mitoxantrone with HiDAc in the treatment of ALL." | 1.28 | Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. ( Ahmed, T; Arlin, ZA; Arnold, P; Baskind, P; Cook, P; Feldman, EJ; Finger, LR; Mittelman, A; Puccio, C; Razis, ED, 1991) |
| "To investigate the effects of mitoxantrone in combination with other anticancer agents, a human T-cell leukemia cell line, MOLT-3, was incubated for 3 days in the presence of two drugs (mitoxantrone and the combined drug) and cell growth inhibition was determined by assay with 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazonium bromide." | 1.28 | Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. ( Akutsu, M; Kano, Y; Suda, K; Suzuki, K, 1992) |
| "9 patients had acute myeloblastic leukemia (AML), (4 relapsed, 5 refractory), 20 had acute lymphoblastic leukemia (ALL) (11 relapsed, 9 refractory) and 6 had chronic myelogenous leukemia (CML) in the blastic phase (BP)." | 1.28 | High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. ( Carcassonne, Y; Gastaut, JA; Launay, MC; Lejeune, C; Maraninchi, D; Richard, B; Sainty, D; Sebahoun, G; Tubiana, N, 1990) |
| "Thirty-nine patients with relapsed acute lymphoblastic leukemia (ALL) and four with primarily refractory ALL were treated with a regimen that included cytarabine 1 gm/m2 (2-hour infusion) twice daily days 1 to 5, mitoxantrone 12mg/m2 daily days 1 to 5, prednisone 0." | 1.28 | Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy. ( Auzanneau, G; Gisselbrecht, C; Gratecos, N; Harousseau, JL; LeBlond, V; Michallet, M; Milpied, N; Sebban, C; Troussard, X; Witz, F, 1990) |
| "Eighteen adults with acute lymphoblastic leukemia (ALL) including 14 previously untreated and 4 relapsed cases were treated with individualized and intensified induction and post-remission therapy." | 1.28 | [Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia--individualized chemotherapy]. ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Toyota, T; Uzuka, Y, 1990) |
| "In stage III and IV Hodgkin's disease, for example, an age-adjusted COPP regimen may be adopted." | 1.28 | [Treatment of elderly patients with hematological malignancies]. ( Mizoguchi, H; Saito, H, 1992) |
| "The three patients with acute lymphocytic leukemia did not achieve CR." | 1.27 | A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol. ( Gorin, NC; Isnard, F; Laporte, JP; Lemonnier, MP; Najman, A, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.85) | 18.7374 |
| 1990's | 49 (47.12) | 18.2507 |
| 2000's | 30 (28.85) | 29.6817 |
| 2010's | 15 (14.42) | 24.3611 |
| 2020's | 6 (5.77) | 2.80 |
| Authors | Studies |
|---|---|
| Atchley, E | 1 |
| Weis, TM | 1 |
| Derkach, A | 1 |
| Galera, PK | 1 |
| Xiao, W | 1 |
| Glass, J | 1 |
| DeWolf, S | 1 |
| Roshal, M | 1 |
| Shah, R | 1 |
| Stump, SE | 1 |
| Ba, D | 1 |
| Li, H | 1 |
| Liu, R | 1 |
| Zhang, P | 1 |
| Tang, Y | 1 |
| August, KJ | 1 |
| Guest, EM | 1 |
| Lewing, K | 1 |
| Hays, JA | 1 |
| Gamis, AS | 1 |
| Messinger, YH | 1 |
| Bostrom, BC | 1 |
| Myint, HH | 1 |
| Tandon, S | 1 |
| Narula, G | 1 |
| Prasad, M | 1 |
| Subramanian, P | 1 |
| Patkar, N | 1 |
| Tembhare, P | 1 |
| Gujral, S | 1 |
| Banavali, S | 1 |
| Tachibana, T | 1 |
| Kanda, J | 1 |
| Ishizaki, T | 1 |
| Najima, Y | 1 |
| Tanaka, M | 1 |
| Doki, N | 1 |
| Fujiwara, SI | 1 |
| Kimura, SI | 1 |
| Onizuka, M | 1 |
| Takahashi, S | 1 |
| Saito, T | 1 |
| Mori, T | 2 |
| Fujisawa, S | 1 |
| Sakaida, E | 1 |
| Miyazaki, T | 1 |
| Aotsuka, N | 1 |
| Gotoh, M | 1 |
| Watanabe, R | 1 |
| Shono, K | 1 |
| Kanamori, H | 1 |
| Kanda, Y | 2 |
| Okamoto, S | 1 |
| Faizan, M | 1 |
| Anwar, S | 1 |
| Khan, S | 1 |
| Nickel, RS | 1 |
| Keller, F | 1 |
| Bergsagel, J | 1 |
| Cooper, T | 1 |
| Daves, M | 1 |
| Sabnis, H | 1 |
| Lew, G | 1 |
| Ahn, JS | 1 |
| Yang, DH | 1 |
| Jung, SH | 1 |
| Lee, JJ | 1 |
| Kim, I | 1 |
| Park, S | 1 |
| Chung, JS | 1 |
| Shin, HJ | 1 |
| Kim, DY | 1 |
| Lee, KH | 1 |
| Moon, JH | 1 |
| Sohn, SK | 1 |
| Song, IC | 1 |
| Jo, DY | 1 |
| Joo, YD | 1 |
| Liedtke, M | 1 |
| Dunn, T | 1 |
| Dinner, S | 1 |
| Coutré, SE | 1 |
| Berube, C | 1 |
| Gotlib, J | 1 |
| Patel, S | 1 |
| Medeiros, B | 1 |
| Jaime-Perez, JC | 1 |
| Colunga-Pedraza, PR | 1 |
| Gutiérrez-Aguirre, CH | 1 |
| Pinzón-Uresti, MA | 1 |
| Cantú-Rodríguez, OG | 1 |
| Herrera-Garza, JL | 1 |
| Gómez-Almaguer, D | 1 |
| Ćmielová, J | 1 |
| Lesná, M | 1 |
| Řezáčová, M | 1 |
| Nelken, B | 1 |
| Cave, H | 1 |
| Leverger, G | 1 |
| Galambrun, C | 1 |
| Plat, G | 1 |
| Schmitt, C | 1 |
| Thomas, C | 1 |
| Vérité, C | 1 |
| Brethon, B | 1 |
| Gandemer, V | 1 |
| Bertrand, Y | 1 |
| Baruchel, A | 1 |
| Rohrlich, P | 1 |
| Ocampo-Garza, J | 1 |
| Herz-Ruelas, ME | 1 |
| Chavez-Alvarez, S | 1 |
| Gómez-Flores, M | 1 |
| Vera-Cabrera, L | 1 |
| Welsh-Lozano, O | 1 |
| Gallardo-Rocha, A | 1 |
| Escalante-Fuentes, WG | 1 |
| Ocampo-Candiani, J | 1 |
| Yamamoto, C | 1 |
| Ito, S | 1 |
| Mashima, K | 1 |
| Umino, K | 1 |
| Minakata, D | 1 |
| Yamasaki, R | 1 |
| Kawasaki, Y | 1 |
| Sugimoto, M | 1 |
| Nakano, H | 1 |
| Ashizawa, M | 1 |
| Okazuka, K | 1 |
| Hatano, K | 1 |
| Sato, K | 1 |
| Oh, I | 1 |
| Fujiwara, S | 1 |
| Ohmine, K | 1 |
| Suzuki, T | 2 |
| Muroi, K | 1 |
| Laskowska, J | 1 |
| Lewandowska-Bieniek, J | 1 |
| Szczepanek, J | 1 |
| Styczyński, J | 2 |
| Tretyn, A | 1 |
| Yeo, KK | 1 |
| Gaynon, PS | 1 |
| Fu, CH | 1 |
| Wayne, AS | 1 |
| Sun, W | 1 |
| Li, Y | 1 |
| Qiu, L | 1 |
| Zou, D | 1 |
| Zhao, Y | 1 |
| Mi, Y | 1 |
| Wang, J | 1 |
| Halicka, HD | 1 |
| Ozkaynak, MF | 1 |
| Levendoglu-Tugal, O | 1 |
| Sandoval, C | 1 |
| Seiter, K | 3 |
| Kajstura, M | 1 |
| Traganos, F | 1 |
| Jayabose, S | 1 |
| Darzynkiewicz, Z | 1 |
| O'Brien, MM | 1 |
| Lacayo, NJ | 1 |
| Lum, BL | 1 |
| Kshirsagar, S | 1 |
| Buck, S | 1 |
| Ravindranath, Y | 2 |
| Bernstein, M | 1 |
| Weinstein, H | 1 |
| Chang, MN | 1 |
| Arceci, RJ | 1 |
| Sikic, BI | 1 |
| Dahl, GV | 1 |
| Parker, C | 1 |
| Waters, R | 1 |
| Leighton, C | 1 |
| Hancock, J | 1 |
| Sutton, R | 1 |
| Moorman, AV | 1 |
| Ancliff, P | 1 |
| Morgan, M | 1 |
| Masurekar, A | 1 |
| Goulden, N | 1 |
| Green, N | 1 |
| Révész, T | 1 |
| Darbyshire, P | 1 |
| Love, S | 1 |
| Saha, V | 1 |
| Schrappe, M | 1 |
| Ozmen, S | 1 |
| Dogru, M | 1 |
| Bozkurt, C | 1 |
| Kocaoglu, AC | 1 |
| Telek, B | 1 |
| Rejtó, L | 1 |
| Kiss, A | 1 |
| Batár, P | 1 |
| Reményi, G | 1 |
| Rák, K | 1 |
| Udvardy, M | 1 |
| Handa, H | 1 |
| Motohashi, S | 1 |
| Isozumi, K | 1 |
| Komatsumoto, S | 1 |
| Nara, M | 1 |
| Dombret, H | 3 |
| Gabert, J | 1 |
| Boiron, JM | 2 |
| Rigal-Huguet, F | 1 |
| Blaise, D | 1 |
| Thomas, X | 3 |
| Delannoy, A | 2 |
| Buzyn, A | 3 |
| Bilhou-Nabera, C | 1 |
| Cayuela, JM | 3 |
| Fenaux, P | 1 |
| Bourhis, JH | 1 |
| Fegueux, N | 1 |
| Charrin, C | 1 |
| Boucheix, C | 1 |
| Lhéritier, V | 3 |
| Espérou, H | 1 |
| MacIntyre, E | 3 |
| Vernant, JP | 3 |
| Fière, D | 2 |
| Wernstedt, P | 1 |
| Brune, M | 1 |
| Andersson, PO | 1 |
| Gustavsson, B | 1 |
| Stockelberg, D | 1 |
| Wadenvik, H | 1 |
| Qiu, HY | 1 |
| Wu, DP | 1 |
| Sun, AN | 1 |
| Chang, WR | 1 |
| Jin, ZM | 1 |
| Miao, M | 1 |
| Tang, XW | 1 |
| Shen, YM | 1 |
| Fu, ZZ | 1 |
| Asnafi, V | 1 |
| Huguet, F | 1 |
| Vey, N | 1 |
| Reman, O | 2 |
| van Imhoff, GW | 1 |
| van der Holt, B | 1 |
| MacKenzie, MA | 1 |
| Ossenkoppele, GJ | 1 |
| Wijermans, PW | 1 |
| Kramer, MH | 1 |
| van 't Veer, MB | 1 |
| Schouten, HC | 2 |
| van Marwijk Kooy, M | 1 |
| van Oers, MH | 1 |
| Raemaekers, JM | 1 |
| Sonneveld, P | 2 |
| Meulendijks, LA | 1 |
| Kluin, PM | 1 |
| Kluin-Nelemans, HC | 1 |
| Verdonck, LF | 2 |
| Di Bona, E | 1 |
| Pogliani, E | 1 |
| Rossi, G | 1 |
| Lerede, T | 1 |
| D'Emilio, A | 1 |
| Vespignani, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 1 |
| Bassan, R | 1 |
| Bao, L | 1 |
| Jiang, B | 1 |
| Huang, XJ | 1 |
| Wang, DB | 1 |
| Qiu, JY | 1 |
| Lu, XJ | 1 |
| Lu, J | 1 |
| Shi, HX | 1 |
| Wang, FR | 1 |
| Lu, DP | 1 |
| Wang, WQ | 1 |
| Liu, XY | 1 |
| Liu, LQ | 1 |
| Kansu, E | 2 |
| Koc, Y | 2 |
| Kars, A | 3 |
| Alakavuklar, M | 1 |
| Tekuzman, G | 2 |
| Firat, D | 2 |
| Karp, JE | 1 |
| Passaniti, A | 1 |
| Gojo, I | 1 |
| Kaufmann, S | 1 |
| Bible, K | 1 |
| Garimella, TS | 1 |
| Greer, J | 1 |
| Briel, J | 1 |
| Smith, BD | 1 |
| Gore, SD | 1 |
| Tidwell, ML | 1 |
| Ross, DD | 1 |
| Wright, JJ | 1 |
| Colevas, AD | 1 |
| Bauer, KS | 1 |
| Giebel, S | 1 |
| Krawczyk-Kulis, M | 1 |
| Adamczyk-Cioch, M | 1 |
| Jakubas, B | 1 |
| Palynyczko, G | 1 |
| Lewandowski, K | 1 |
| Dmoszynska, A | 1 |
| Skotnicki, A | 1 |
| Nowak, K | 1 |
| Holowiecki, J | 1 |
| Su, Y | 1 |
| Lee, SH | 1 |
| Sinko, PJ | 1 |
| Salonen, JH | 1 |
| de Labarthe, A | 1 |
| Rousselot, P | 1 |
| Huguet-Rigal, F | 1 |
| Delabesse, E | 1 |
| Witz, F | 2 |
| Maury, S | 1 |
| Réa, D | 1 |
| Vekemans, MC | 1 |
| Pigneux, A | 1 |
| Escoffre, M | 1 |
| Chalandon, Y | 1 |
| Ifrah, N | 1 |
| Yoshimi, A | 1 |
| Taoka, K | 1 |
| Nakasone, H | 1 |
| Iijima, K | 2 |
| Kida, M | 1 |
| Iki, S | 1 |
| Urabe, A | 1 |
| Usuki, K | 1 |
| Cartwright, MS | 1 |
| Jeffery, DR | 1 |
| Lewis, ZT | 1 |
| Koty, PP | 1 |
| Stewart, WT | 1 |
| Molnár, I | 1 |
| Tobinai, K | 1 |
| Takeyama, K | 1 |
| Arima, F | 1 |
| Aikawa, K | 1 |
| Kobayashi, T | 1 |
| Hanada, S | 1 |
| Kasai, M | 1 |
| Ogura, M | 1 |
| Sueoka, E | 1 |
| Mukai, K | 1 |
| Tajima, K | 1 |
| Fukuda, H | 1 |
| Shirakawa, S | 1 |
| Hotta, T | 1 |
| Masanori, S | 1 |
| Sastre, JL | 1 |
| Pérez-Oteyza, J | 1 |
| López, J | 1 |
| Cerveró, C | 1 |
| Sánchez-Sousa, A | 1 |
| García-Laraña, J | 1 |
| Cancelas, JA | 1 |
| Odriozola, J | 1 |
| Navarro, JL | 1 |
| Inhorn, RC | 1 |
| Aster, JC | 1 |
| Roach, SA | 1 |
| Slapak, CA | 1 |
| Soiffer, R | 1 |
| Tantravahi, R | 1 |
| Stone, RM | 1 |
| Kawano, Y | 1 |
| Takaue, Y | 1 |
| Saito, S | 1 |
| Sato, J | 1 |
| Shimizu, T | 1 |
| Suzue, T | 1 |
| Hirao, A | 1 |
| Okamoto, Y | 1 |
| Abe, T | 1 |
| Watanabe, T | 1 |
| Kantarjian, HM | 3 |
| Estey, E | 1 |
| O'Brien, S | 3 |
| Anaissie, E | 2 |
| Beran, M | 2 |
| Pierce, S | 1 |
| Robertson, L | 1 |
| Keating, MJ | 3 |
| Klumper, E | 2 |
| Pieters, R | 4 |
| den Boer, ML | 1 |
| Huismans, DR | 3 |
| Loonen, AH | 1 |
| Veerman, AJ | 4 |
| Ludescher, C | 1 |
| Eisterer, W | 1 |
| Hilbe, W | 1 |
| Gotwald, M | 1 |
| Hofmann, J | 1 |
| Zabernigg, A | 1 |
| Cianfriglia, M | 1 |
| Thaler, J | 2 |
| Wells, RJ | 1 |
| Odom, LF | 1 |
| Gold, SH | 1 |
| Feusner, J | 1 |
| Krill, CE | 1 |
| Waldron, P | 1 |
| Moulton, TA | 1 |
| Knoppell, E | 1 |
| White, ML | 1 |
| Cairo, MS | 1 |
| Welborn, JL | 1 |
| Keskin, A | 1 |
| Tombuloğlu, M | 1 |
| Atamer, MA | 1 |
| Büyükkeçeci, F | 1 |
| Kaspers, GL | 1 |
| van Zantwijk, I | 1 |
| Hählen, K | 2 |
| de Waal, FC | 1 |
| van Wering, ER | 1 |
| Schiller, G | 1 |
| Lee, M | 1 |
| Territo, M | 1 |
| Gajewski, J | 1 |
| Nimer, S | 1 |
| Hwang, WS | 1 |
| Chen, LM | 1 |
| Huang, SH | 1 |
| Wang, CC | 1 |
| Tseng, MT | 1 |
| Sotomatsu, M | 1 |
| Yugami, S | 1 |
| Shitara, T | 1 |
| Kuroume, T | 1 |
| Feldman, EJ | 3 |
| Alberts, DS | 1 |
| Arlin, Z | 1 |
| Ahmed, T | 3 |
| Mittelman, A | 2 |
| Baskind, P | 2 |
| Peng, YM | 1 |
| Baier, M | 1 |
| Plezia, P | 1 |
| Cheson, BD | 1 |
| Nakajima, H | 1 |
| Kizaki, M | 1 |
| Kawai, Y | 1 |
| Ishida, A | 1 |
| Tokuhira, M | 1 |
| Watanabe, K | 1 |
| Ikeda, Y | 1 |
| Weiss, M | 3 |
| Maslak, P | 1 |
| Feldman, E | 1 |
| Berman, E | 1 |
| Bertino, J | 1 |
| Gee, T | 1 |
| Megherian, L | 1 |
| Scheinberg, D | 1 |
| Golde, D | 1 |
| Nishikawa, K | 1 |
| Ohshima, A | 1 |
| Miura, I | 1 |
| Chubachi, A | 1 |
| Hashimoto, K | 1 |
| Nimura, T | 1 |
| Utsumi, S | 1 |
| Takahashi, N | 1 |
| Hayashi, Y | 1 |
| Seto, M | 1 |
| Ueda, R | 1 |
| Miura, AB | 1 |
| Kern, W | 2 |
| Schleyer, E | 2 |
| Unterhalt, M | 2 |
| Wörmann, B | 2 |
| Büchner, T | 3 |
| Hiddemann, W | 3 |
| Stein, RS | 1 |
| Greer, JP | 1 |
| Flexner, JM | 1 |
| Goodman, S | 1 |
| Wolff, SN | 1 |
| Dekker, AW | 1 |
| van't Veer, MB | 1 |
| Sizoo, W | 1 |
| Haak, HL | 1 |
| van der Lelie, J | 1 |
| Ossenkoppele, G | 1 |
| Huijgens, PC | 1 |
| Willemze, R | 1 |
| van Putten, WL | 1 |
| Löwenberg, B | 1 |
| Benekli, M | 1 |
| Güler, N | 2 |
| Hongo, T | 1 |
| Yajima, S | 1 |
| Sakurai, M | 2 |
| Horikoshi, Y | 1 |
| Hanada, R | 1 |
| Higashigawa, M | 1 |
| Hori, H | 1 |
| Hirayama, M | 1 |
| Kawasaki, H | 1 |
| Ido, M | 1 |
| Azuma, E | 1 |
| Inukai, T | 1 |
| Sugita, K | 1 |
| Goi, K | 1 |
| Tezuka, T | 1 |
| Kojika, S | 1 |
| Kagami, K | 1 |
| Kinoshita, A | 1 |
| O-Koyama, T | 1 |
| Nakazawa, S | 1 |
| Mariańska, B | 2 |
| Apel, D | 2 |
| Seferyńska, I | 1 |
| Maj, S | 2 |
| Nagler, A | 1 |
| Soni, S | 1 |
| Samuel, S | 1 |
| Or, R | 1 |
| Akpek, G | 1 |
| Baltali, E | 1 |
| Barista, I | 1 |
| Güllü, I | 1 |
| Ozisik, Y | 1 |
| Raanani, P | 1 |
| Shpilberg, O | 1 |
| Gillis, S | 1 |
| Avigdor, A | 1 |
| Hardan, I | 1 |
| Berkowicz, M | 1 |
| Sofer, O | 1 |
| Lossos, I | 1 |
| Chetrit, A | 1 |
| Ben-Yehuda, D | 1 |
| Ben-Bassat, I | 1 |
| Rosen, PJ | 1 |
| Rankin, C | 1 |
| Head, DR | 1 |
| Boldt, DH | 1 |
| Luthardt, FW | 1 |
| Norwood, T | 1 |
| Pugh, RP | 1 |
| Karanes, C | 1 |
| Appelbaum, FR | 1 |
| Salvucci, M | 1 |
| Zanchini, R | 1 |
| Molinari, A | 1 |
| Zuffa, E | 1 |
| Poletti, V | 1 |
| Poletti, G | 1 |
| Zaccaria, A | 1 |
| Schuurhuis, GJ | 1 |
| Wysocki, M | 1 |
| Ribeiro, RC | 1 |
| Fletcher, BD | 1 |
| Kennedy, W | 1 |
| Harrison, PL | 1 |
| Neel, MD | 1 |
| Kaste, SC | 1 |
| Sandlund, JT | 1 |
| Rubnitz, JE | 1 |
| Razzouk, BI | 1 |
| Relling, MV | 1 |
| Pui, CH | 1 |
| Sreekantaiah, C | 1 |
| Pozzuoli, M | 1 |
| Weisberger, J | 1 |
| Liu, D | 1 |
| Papageorgio, C | 1 |
| Kancherla, R | 1 |
| Braess, J | 1 |
| Wittmer, E | 1 |
| Ohnesorge, J | 1 |
| Zwaan, CM | 1 |
| Kaspers, GJ | 1 |
| Janka-Schaub, GE | 1 |
| van Zantwijk, CH | 1 |
| de Vries, E | 1 |
| Rots, MG | 1 |
| Peters, GJ | 1 |
| Jansen, G | 1 |
| Creutzig, U | 1 |
| Vyas, V | 1 |
| Shah, SA | 1 |
| Patel, KM | 1 |
| Parekh, BB | 1 |
| Nath, SV | 1 |
| Hussain, BM | 1 |
| Saito, H | 1 |
| Mizoguchi, H | 1 |
| Bernasconi, C | 2 |
| Lazzarino, M | 1 |
| Morra, E | 1 |
| Alessandrino, EP | 1 |
| Pagnucco, G | 1 |
| Resegotti, L | 1 |
| Locatelli, F | 1 |
| Ficarra, F | 1 |
| Bacigalupo, A | 1 |
| Carella, AM | 1 |
| Liso, V | 1 |
| Specchia, G | 1 |
| Capalbo, S | 1 |
| Pavone, V | 1 |
| Iacobazzi, A | 1 |
| Iaculli, ML | 1 |
| Dione, R | 1 |
| Pansini, N | 1 |
| Kano, Y | 1 |
| Suzuki, K | 1 |
| Akutsu, M | 1 |
| Suda, K | 1 |
| Estey, EH | 2 |
| Rios, MB | 1 |
| Gutterman, J | 1 |
| Graham, ML | 1 |
| Estrada, J | 1 |
| Ragab, AH | 1 |
| Starling, KA | 1 |
| Rosen, D | 1 |
| Wilkenson, RW | 1 |
| Wilkerson, RW | 1 |
| Rozmysłowicz, T | 1 |
| Pałynyczko, G | 1 |
| Mazur, J | 1 |
| Konecki, R | 1 |
| Hołowiecki, J | 1 |
| Rudzka, E | 1 |
| Lawniczek, T | 1 |
| Flavell, SU | 1 |
| Flavell, DJ | 1 |
| Arlin, ZA | 2 |
| Finger, LR | 1 |
| Cook, P | 1 |
| Puccio, C | 1 |
| Arnold, P | 1 |
| Razis, ED | 1 |
| Cuttner, J | 1 |
| Mick, R | 1 |
| Budman, DR | 1 |
| Mayer, RJ | 1 |
| Lee, EJ | 1 |
| Henderson, ES | 1 |
| Weiss, RB | 1 |
| Paciucci, PA | 1 |
| Sobol, R | 1 |
| Davey, F | 1 |
| Bezwoda, WR | 1 |
| Hutchinson, RM | 1 |
| Winfield, DA | 1 |
| de Bock, R | 1 |
| Mandelli, F | 1 |
| Ferrant, A | 1 |
| Bosly, A | 1 |
| Chatelain, C | 1 |
| Doyen, C | 1 |
| Martiat, P | 1 |
| Michaux, JL | 1 |
| Sokal, G | 1 |
| Walters, RL | 1 |
| Schachner, J | 1 |
| McCredie, KB | 1 |
| Freireich, EJ | 1 |
| Coccia-Portugal, MA | 1 |
| Falkson, G | 1 |
| Uys, A | 1 |
| Linkesch, W | 1 |
| Gattringer, C | 1 |
| Konwalinka, G | 1 |
| Lejeune, C | 1 |
| Tubiana, N | 1 |
| Gastaut, JA | 1 |
| Maraninchi, D | 1 |
| Richard, B | 1 |
| Launay, MC | 1 |
| Sainty, D | 1 |
| Sebahoun, G | 1 |
| Carcassonne, Y | 1 |
| Milpied, N | 1 |
| Gisselbrecht, C | 1 |
| Harousseau, JL | 1 |
| Sebban, C | 1 |
| Troussard, X | 1 |
| Gratecos, N | 1 |
| Michallet, M | 1 |
| LeBlond, V | 1 |
| Auzanneau, G | 1 |
| Uzuka, Y | 1 |
| Saito, Y | 1 |
| Takahashi, H | 1 |
| Komatsu, M | 1 |
| Ito, T | 1 |
| Toyota, T | 1 |
| Heil, G | 1 |
| Schumacher, K | 1 |
| Diedrich, H | 1 |
| Maschmeyer, G | 1 |
| Ho, AD | 1 |
| Planker, M | 1 |
| Gerith-Stolzenburg, S | 1 |
| Donhuijsen-Ant, R | 1 |
| Gao, HR | 1 |
| Laporte, JP | 1 |
| Gorin, NC | 1 |
| Lemonnier, MP | 1 |
| Isnard, F | 1 |
| Najman, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA[NCT00002912] | Phase 1 | 3 participants (Actual) | Interventional | 1997-01-31 | Completed | ||
| ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL)[NCT00967057] | Phase 3 | 470 participants (Anticipated) | Interventional | 2002-10-31 | Completed | ||
| Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study[NCT04224571] | Phase 2 | 208 participants (Actual) | Interventional | 2018-09-14 | Completed | ||
| A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4)[NCT00002700] | Phase 3 | 392 participants (Anticipated) | Interventional | 1995-08-31 | Completed | ||
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia[NCT00494897] | Phase 4 | 374 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| "Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17"[NCT00475280] | Phase 2 | 102 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for mitoxantrone and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2002 |
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Biomarkers, Tumor; Child; Chromosome Aberrations; Clinical Tri | 2003 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Col | 1996 |
Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Disease-Free Survival; Female | 1998 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2001 |
Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL).
Topics: Amsacrine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor | 1989 |
27 trials available for mitoxantrone and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fema | 2014 |
A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; | 2016 |
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfam | 2010 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2010 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2010 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2010 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginas | 2010 |
Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2005 |
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2005 |
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Fema | 2005 |
[Clinical study on mitoxantrone contained regimen for treatment of newly diagnosed childhood acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Drug Administr | 2004 |
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2005 |
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease- | 2006 |
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; H | 2007 |
Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Eto | 2007 |
Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Leukoc | 1993 |
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr | 1993 |
Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relat | 1996 |
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Topics: Adolescent; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; An | 1997 |
[Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Femal | 1998 |
Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Comb | 1998 |
Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Disease-Free Survival; Female | 1998 |
A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; | 2000 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free | 2001 |
Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1992 |
Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Female; Humans; | 1991 |
[Preliminary results of the treatment of acute leukemia with mitoxantrone].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra | 1991 |
Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Dose-Response Relat | 1991 |
Mitoxantrone for refractory and relapsed acute leukemia.
Topics: Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Multicen | 1990 |
[Phase II clinical trial on mitoxantrone].
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Drug Evaluation; Female; Humans; Leukopenia; Lymphoma, No | 1989 |
70 other studies available for mitoxantrone and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell T | 2023 |
Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model.
Topics: Antigens, CD19; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line; Humans; Immunotherapy, Adop | 2023 |
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bortezomib; Child; Child, | 2020 |
Bortezomib-based four-drug induction does induce a response in advanced relapsed ALL but cure remains elusive.
Topics: Asparaginase; Bortezomib; Child; Dexamethasone; Humans; Mitoxantrone; Polyethylene Glycols; Precurso | 2020 |
Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; | 2020 |
Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
Topics: Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 2021 |
Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2018 |
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Dexamethasone; Dr | 2014 |
Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hu | 2015 |
Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Cohort Studies; Disease-Free Surviva | 2015 |
Subcellular Localization of Proteins Responding to Mitoxantrone-Induced DNA Damage in Leukaemic Cells.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Checkpoint Kinase 2; Cyclin-Dependent Kinase | 2015 |
Disseminated fusariosis with endophthalmitis after skin trauma in acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents; Endophthalmitis; Fusariosis; Humans; Male; Middle Aged; Mitoxantrone; Precurs | 2016 |
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; | 2016 |
Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Child; Cluster Analysis; Comparative Genomic | 2016 |
Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bortezomib; Child; Child, | 2016 |
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromos | 2009 |
DNA damage response as a biomarker in treatment of leukemias.
Topics: Adolescent; Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Cell Cycle Proteins; Ch | 2009 |
Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Probable cytarabine-induced acral erythema: report of 2 pediatric cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Etoposide; | 2013 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigen | 2002 |
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Stu | 2002 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2002 |
[Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte C | 2004 |
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; | 2005 |
Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as T | 1989 |
Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2006 |
Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparagina | 2006 |
[Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasm | 2006 |
Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Female; Humans; | 2007 |
[Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases].
Topics: Adult; Aged; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fatal Outco | 1994 |
Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Cytarabine; Dau | 1993 |
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; H | 1993 |
In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Bone Marrow; Child; Daunorubicin; Dose-Response Relationsh | 1995 |
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, | 1994 |
Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Aspartate-Ammonia Ligase; Clinical | 1994 |
Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; | 1994 |
In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Daunorubicin; Doxorubicin; Drug Resistan | 1994 |
Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Col | 1993 |
Dipyridamole enhancement of drug sensitivity in acute lymphoblastic leukemia cells.
Topics: Administration, Oral; Antineoplastic Agents; Bone Marrow; Child; Dipyridamole; Dose-Response Relatio | 1993 |
Clinical trials referral resource. Acute lymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clin | 1993 |
CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: a case report.
Topics: Antigens, CD7; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Femal | 1996 |
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 1996 |
11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; DNA Topoisomeras | 1996 |
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1997 |
Mitoxantrone-induced bradycardia.
Topics: Adult; Antineoplastic Agents; Bradycardia; Female; Humans; Male; Middle Aged; Mitoxantrone; Precurso | 1997 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1997 |
Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Co | 1997 |
Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Blast Crisis; Cell Division; Cell Lin | 1998 |
Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationshi | 1999 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; I | 2000 |
In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Bone Marrow Cells; Child; Child | 2000 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, R | 2001 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; | 2002 |
Acute lymphocytic leukemia CNS disease presenting as central diabetes insipidus.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Chlorambucil; Deamino Arginine Vasopre | 2002 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1992 |
Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; | 1992 |
Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Division; Cell Line; Data Interpret | 1992 |
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fever; Granulocyte-Macrophage Col | 1992 |
The anti-mitozantrone monoclonal antibody NO-1, protects acute leukaemia cell lines from the cytotoxic effects of mitozantrone.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cell Line; Humans; Mitoxantrone; Precursor Cell Lymph | 1991 |
Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug A | 1991 |
Acute lymphoblastic leukemia in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male | 1990 |
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; | 1990 |
Mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Evaluation; Female; Humans; Le | 1990 |
Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemothe | 1990 |
High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
Topics: Adolescent; Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, In | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1990 |
[Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia--individualized chemotherapy].
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1990 |
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Human | 1988 |